Lessons learned from contamination with endotoxin originated from the supplement in the cell culture medium

Koaki Uehara1, Eriko Oshiro1, Atsushi Ochiai1

  • 1Social Medical Corporation Yuuaikai, Yuuai Medical Center, Advanced Medical Research Center, 50-5, Yone, Tomigusuku-shi, Okinawa 901-0224, Japan.

Regenerative Therapy
|April 10, 2024
PubMed
Abstract

Insights

Endotoxin contamination in cell-based products was traced to cholera toxin reagents. Implementing reagent testing or validated certificates of analysis is crucial for ensuring product safety and quality.

Area of Science:

  • Microbiology
  • Biotechnology
  • Cell Therapy

Background:

  • Endotoxins, pyrogens from Gram-negative bacteria, necessitate strict control in cell-based medicinal product fabrication.
  • Elevated endotoxin levels were detected in the culture supernatant of autologous oral mucosal epithelial cell sheets during a clinical study.

Purpose of the Study:

  • To investigate the source of endotoxin contamination in autologous oral mucosal epithelial cell sheets used in a clinical study.
  • To identify specific reagents responsible for endotoxin contamination in cell culture processes.

Main Methods:

  • Endotoxin concentrations were measured in culture supernatants, unused culture media, and reagents used for media preparation.
  • Samples included epithelial cell sheets, culture media components, and cholera toxin products.

Main Results:

  • Endotoxin exceeded acceptable limits in both unused culture medium and epithelial cell sheet supernatant.
  • Reagents for culture medium preparation were below limits, except for cholera toxin.
  • Three lots of cholera toxin products showed high endotoxin concentrations, identifying it as the contamination source.

Conclusions:

  • Cholera toxin products were identified as the primary source of endotoxin contamination.
  • Reagent quality control, including endotoxin testing or Certificates of Analysis, is vital for preventing contamination in cell-based product manufacturing.
  • Proactive measures in clinical research facilities are essential for ensuring the safety of cell-based medicinal products.